- Cambridge, Massachusetts, United States
- Hybrid
- Full-time · Director
- $247K–$278K per year
- 15+ years
Provide strategic and technical leadership across Amylyx’s clinical and late-stage pipeline, including the Phase III synthetic peptide avexitide, Phase I antisense oligonucleotide AMX0114, and Phase 2 small molecule AMX0035.
Compensation
$247,000—$278,000 USD
Responsibilities
- Lead technical development across Amylyx’s pipeline, ensuring plans are scientifically rigorous, phase-appropriate, and aligned with clinical, regulatory, quality, supply, and business objectives.
- Serve directly or through direct reports as the Technical Development lead on CMC asset teams, accountable to provide clear technical requirements, risks, timelines, decision options, regulatory filing materials, and clinical supplies.
- Provide input into target product profiles ensuring technical feasibility and translating into critical quality attributes and critical process parameters.
- Partner with CMC Team Strategy lead(s) to integrate technical development plans into overall asset strategies.
- Proactively identify critical path activities, technical risks, resource needs, and budget implications; develop practical mitigation plans and contingency strategies in collaboration with internal and external teams.
Requirements
- Advanced degree in chemistry, chemical engineering, pharmaceutical sciences, biochemistry, or a related scientific or engineering discipline
- Ph.D. preferred
- Nice to have: Global CMC submissions support
